Summary

OneSource Specialty Pharma Limited announced a strong recovery in Q4FY26, with revenue jumping 47% quarter-on-quarter to ₹4,282 million and EBITDA expanding over 5x to ₹919 million. This performance was attributed to broad business momentum and successful semaglutide launches in India. Despite the robust quarterly performance, the full fiscal year 2026 saw a 2% year-on-year revenue decline to ₹14,216 million and a 35% fall in EBITDA to ₹3,042 million. Management expressed confidence in sustaining growth momentum into FY27, citing new product launches and pipeline expansion, while reiterating its ambitious FY28 guidance.

Key Highlights

1. 1

   Q4FY26 revenue surged by 47% quarter-on-quarter to ₹4,282 million, driven by growth across all service offerings and India semaglutide commercial launches.

2. 2

   EBITDA for Q4FY26 expanded over 5x quarter-on-quarter to ₹919 million, reflecting operating leverage on higher CSA revenues.

3. 3

   Adjusted Profit After Tax (PAT) for Q4FY26 stood at ₹390 million, a significant turnaround from a loss in the previous quarter, with an adjusted EPS of ₹3.4.

4. 4

   For the full fiscal year 2026, revenue was ₹14,216 million, marking a slight decline of 2% year-on-year.

5. 5

   FY26 EBITDA decreased by 35% year-on-year to ₹3,042 million, with the EBITDA margin at 21%.

6. 6

   Adjusted PAT for FY26 was ₹739 million, a 68% decrease year-on-year, resulting in an adjusted EPS of ₹6.5.

7. 7

   OneSource reaffirmed its FY28 guidance, targeting approximately $400 million in organic revenue with an EBITDA margin of around 40%.